Introduction {#Sec1}
============

Cardiovascular disease (CVD) is the leading cause of death after kidney transplantation (KT)^[@CR1]^, and the incidence of CVD is higher in KT recipients than in the general population^[@CR2]^. Numerous studies reported that the risk of CVD is elevated after KT because of non-traditional risk factors such as immunologic alteration and the various medications related to the transplantation surgery^[@CR3]--[@CR9]^. Atherosclerosis is an underlying chronic inflammatory condition in CVD, and the role of the immune system in the development of atherosclerosis is well descried in the literature^[@CR10]^. B lymphocytes were considered to have a protective effect against atherosclerosis until nearly 2010^[@CR11]^. However, recent experimental studies revealed opposing roles of different B cell subsets, atheroprotective B1 cells and atherogenic B2 cells^[@CR12]--[@CR16]^. Those studies also demonstrated reduced atherosclerotic plaques in atherosclerosis-prone mice treated with rituximab, a B cell-depleting anti-CD20 monoclonal antibody. The potential of B cell targeting as a treatment for atherogenesis has been suggested^[@CR17]^, although heretofore there was no comparative human study of B cell depletion and atherosclerotic CVD (ASCVD).

Rituximab was introduced as an effective alternative to splenectomy for desensitization of patients requiring KT^[@CR18]^. Given the excellent outcomes reported in ABO-incompatible and crossmatch-positive KT^[@CR19],[@CR20]^, rituximab use in the realm of KT is increasing. Herein, we sought to explore the effects of rituximab induction on ASCVD in the aftermath of KT through propensity-matched analysis.

Results {#Sec2}
=======

Descriptions of entire cohort {#Sec3}
-----------------------------

For the 1299 eligible patients, mean age was 45.3 ± 11.3 years, and there were 761 men (58.6%). Nine hundred forty-five patients (72.7%) underwent living donor kidney transplantation (LDKT), and in 126 (9.7%), retransplantation took place. One hundred ten grafts were lost including 46 deaths (7 as cardiovascular deaths) and 77 ASCVDs occurred during a mean follow-up of 82.3 ± 35.5 months. Rituximab was administered preoperatively to 245 patients (18.9%; 117 ABO incompatibility, 43 crossmatch positivity, 13 simultaneous ABO incompatibility and crossmatch positivity, and 72 high reactivity to panel antibodies). Among patients treated with rituximab, 167 (68.1%) were given standard doses (375 mg/m^2^), and 78 (31.9%) received reduced doses (200 mg).

Baseline characteristics before and after matching {#Sec4}
--------------------------------------------------

Table [1](#Tab1){ref-type="table"} shows baseline characteristics of rituximab and control group patients. Before matching, there were differences in some variables, such as sex, deceased donor, duration of dialysis, retransplantation, tacrolimus use, pretransplant diabetes melitus (DM), baseline Low-density lipoprotein (LDL), biopsy-proven acute rejection (BPAR) within 1 year, and estimated glomerular filtration rate (eGFR) at 1 month. In 1:2 propensity score matching, 239 patients given rituximab were matched with 401 controls. Most variables (except BPAR within 1 year) were then balanced within the two groups (see *Statistical analysis*).Table 1Baseline characteristics before and after propensity score matching.VariablesBefore matchingAfter matchingRituximab (n = 245)Control (n = 1054)*P*Rituximab (n = 239)Control (n = 401)*P*Age (years)46.1 ± 10.545.1 ± 11.50.21046.0 ± 10.644.6 ± 12.20.144Sex, males116 (47.3%)645 (61.2%)\<0.001115 (48.1%)207 (51.6%)0.391Body mass index (kg/m^2^)22.3 ± 3.422.5 ± 3.30.29822.3 ± 3.422.3 ± 3.50.754Deceased donor20 (8.2%)334 (31.7%)\<0.00120 (8.4%)40 (10.0%)0.500Dialysis duration (months)4 (27)13 (73)\<0.0014 (28)5 (28)0.429Retransplantation39 (15.9%)87 (8.3%)\<0.00133 (13.8%)38 (9.5%)0.091Use of tacrolimus (vs. cyclosporin)237 (96.7%)776 (73.6%)\<0.001231 (96.7%)384 (95.8%)0.573Pretrasnplant alcohol use47 (19.2%)184 (17.5%)0.52447 (19.7%)61 (15.2%)0.146Pretransplant smoking47 (19.2%)215 (20.4%)0.66947 (19.7%)77 (19.2%)0.886Pretransplant DM71 (29.0%)193 (18.3%)\<0.00166 (27.6%)105 (26.2%)0.692Pretransplant ASCVD history19 (7.8%)71 (6.7%)0.57218 (7.5%)31 (7.7%)0.927SBP ≥ 140 mm Hg111 (50.9%)568 (57.5%)0.074109 (51.4%)214 (56.3%)0.251DBP ≥ 90 mm Hg84 (38.7%)436 (44.2%)0.13883 (39.3%)168 (44.3%)0.240Total cholesterol ≥ 240 (mg/dL)6 (2.4%)30 (2.8%)0.7336 (2.5%)8 (2.0%)0.666LDL cholesterol ≥ 100 (mg/dL)39 (15.9%)323 (30.7%)\<0.00139 (16.3%)76 (19.0%)0.401Use of statin51 (20.8%)214 (20.3%)0.85848 (20.1%)90 (22.4%)0.482Biopsy-proven acute rejection within 1 year64 (26.1%)130 (12.3%)\<0.00162 (25.9%)41 (10.2%)\<0.001eGFR^a^ at 1 month (mL/min)66.4 ± 24.662.9 ± 21.30.04265.7 ± 24.365.1 ± 20.60.715^a^Calculated using Chronic Kidney Disease Epidemiology (CKD-EPI) formula.ASCVD, atherosclerotic cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; KT, kidney transplantation; LDL, low density lipoprotein; SBP, systolic blood pressure.

ASCVD and all-cause death in matched cohort {#Sec5}
-------------------------------------------

In the matched cohort, patients undergoing rituximab induction experienced only 6 ASCVD events within 8 years after KT (1 fatal myocardial infarction \[MI\] and 5 percutaneous coronary revascularizations). However, 35 ASCD events were recorded in the control group (3 fatal MIs, 1 nonfatal MI, 8 percutaneous coronary revascularizations, 4 coronary artery bypass surgeries, 8 acute cerebral infarctions, and 11 peripheral artery revascularizations). The cumulative rate of ASCVD was significantly lower in rituximab-treated patients than in controls (3.7% vs. 11.2%, *P* = 0.012; Fig. [1a](#Fig1){ref-type="fig"}). Seven deaths occurred in the rituximab group, including one cardiovascular death. Among 13 posttransplant deaths in the control group, three were from cardiovascular causes. During the 8-year follow-up period, rituximab-treated patients and controls showed no significant difference in all-cause death (2.9% vs. 4%, *P* = 0.943; Fig. [1b](#Fig1){ref-type="fig"}). ASCVD events and causes of death in both groups are detailed in Table [2](#Tab2){ref-type="table"}.Figure 1Comparison of (**a**) ASCVD and (**b**) all cause death after KT by rituximab induction in the matched cohort. KT, kidney transplantation; ASCVD, atherosclerotic cardiovascular disease.Table 2The first ASCVD events and cause of mortality over 8 years in the matched cohort.Rituximab (n = 239)Control (n = 401)**ASCVD events**Total635Fatal MI13Non-fatal MI01Percutaneous coronary revascularization58Coronary artery bypass surgery04Acute cerebral infarction08Peripheral artery revascularization011**Cause of mortality**Total713Cardiovascular13Infection39Gastrointestinal bleeding10Malignancy01Liver disease10Unknown10ASCVD, atherosclerotic cardiovascular disease; MI, myocardial infarction.

Serial comparison of blood pressure, renal function, and LDL {#Sec6}
------------------------------------------------------------

Figure [2](#Fig2){ref-type="fig"} depicts changes over time in several variables known to be CVD risk factors. Although systolic blood pressure (SBP) and diastolic blood pressure (DBP) were higher in treated patients (vs controls) 1 month after transplantation, both levels appeared similar thereafter at most points in time. eGFR did not differ by group up to 1 year posttransplantation, surging higher in controls than in rituximab-treated patients at Years 2 and 3. LDL was higher in controls at 6 months only, approaching levels similar to treated patients for the duration of follow-up.Figure 2Serial comparison of (**a**) SBP, (**b**) DBP, (**c**) eGFR and (**d**) LDL between the rituximab group and the matched controls. \**P* \< 0.05, DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LDL, low density lipoprotein; SBP, systolic blood pressure.

Cox proportional hazard analysis for ASCVD {#Sec7}
------------------------------------------

In multivariable Cox analysis of matched cohort data (Table [3](#Tab3){ref-type="table"}), rituximab emerged as independently protective of ASCVD developing after KT (hazard ratio \[HR\] = 0.34, 95% confidence interval \[CI\]: 0.14--0.83). Other risk factors for ASCVD were maleness (HR = 2.14, 95% CI: 1.01--4.52), duration of dialysis (HR = 1.07, 95% CI: 1.03--1.11 \[per 6 months\]), retransplantation (HR = 2.90, 95% CI: 1.34--6.27), pretransplant DM (HR = 3.68, 95% CI: 1.71--7.88), and pretransplant ASCVD history (HR = 4.92, 95% CI: 2.42--10.03). BPAR within 1 year, which differed in rituximab and control groups, was not a risk factor (HR = 0.95, 95% CI: 0.40--2.25). LDL cholesterol, statin use, blood pressure, and eGFR at 1 month were not associated with posttransplant ASCVD.Table 3Risk factors associated with ASCVD in matched cohort.VariablesUnivariable CoxMultivariable Cox^a^HR (95% CI)*P*HR (95% CI)*P*Age (per 5 years)1.32 (1.15--1.53)\<0.001Sex, male3.25 (1.59--6.63)0.0012.14 (1.01--4.52)0.047Body mass index ≥ 25 kg/m^2^1.21 (0.58--2.53)0.618Deceased donor1.20 (0.43--3.36)0.735Dialysis duration (per 6 months)1.05 (1.02--1.09)0.0021.07 (1.03--1.11)\<0.001Retransplantation2.42 (1.15--5.07)0.0192.90 (1.34--6.27)0.007Pretrasnplant alcohol use1.37 (0.63--2.99)0.423Pretransplant smoking2.11 (1.07--4.15)0.031Pretransplant DM5.98 (3.15--11.33)\<0.0013.68 (1.71--7.88)0.001Pretransplant ASCVD history9.29 (4.94--17.47)\<0.0014.92 (2.42--10.03)\<0.001Baseline SBP ≥ 140 mm Hg1.15 (0.61--2.16)0.672Baseline DBP ≥ 90 mm Hg0.62 (0.31--1.23)0.169LDL cholesterol ≥ 100 mg/dL1.24 (0.59--2.60)0.565Use of statin1.57 (0.80--3.09)0.187Biopsy proven acute rejection within 1 year0.95 (0.40--2.25)0.902eGFR^b^ at 1 month (per 10 mL/min)0.97 (0.83--1.12)0.633Rituximab induction0.34 (0.14--0.82)0.0170.34 (0.14--0.83)0.017^a^Multivariable Cox analysis was performed by backward stepwise selection with *P*-value threshold 0.05.^b^Calculated using Chronic Kidney Disease Epidemiology (CKD-EPI) formula.ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; KT, kidney transplantation; LDL, low density lipoprotein; SBP, systolic blood pressure.

Subgroup analysis {#Sec8}
-----------------

Subjects of the matched cohort were stratified by pretransplant DM, sex, pretransplant dialysis, and age ≥ 50 years, followed by analyzing HRs of rituximab treatment for ASCVD in each subgroup (Fig. [3](#Fig3){ref-type="fig"}). There was no apparent interaction between any subgroup and rituximab treatment. HRs of patients with and without DM were 0.34 (95% CI: 0.12--0.99; *P* = 0.048) and 0.32 (95% CI: 0.07--1.15; *P* = 0.140), respectively. Respective HRs of male and female patients were 0.45 (95% CI: 0.17--1.18; *P* = 0.103) and 0.20 (95% CI: 0.03--1.57; *P* = 0.125), neither showing significance. In the presence and absence of dialysis prior to KT, HRs were 0.25 (95% CI: 0.07--0.82; *P* = 0.023) and 0.81 (95% CI: 0.15--4.31; *P* = 0.805), respectively; and HRs of patients beyond or less than 50 years old were 0.61 (95% CI: 0.20--1.88; *P* = 0.020) and 0.61 (95% CI: 0.20--1.88; *P* = 0.390), respectively.Figure 3Hazard ratios for posttransplant ASCVD in clinical subgroups treated with rituximab. From matched cohort, subjects were stratified by DM, sex, pretransplant dialysis and 50 years of age. CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio; KT, kidney transplantation; ASCVD, atherosclerotic cardiovascular disease.

Discussion {#Sec9}
==========

In the propensity-matched analysis herein, rituximab induction significantly reduced the incidence of ASCVD developing after KT. Prior *in vivo* studies demonstrated that the use of anti-B-cell agents could be an effective therapeutic approach for the treatment and prevention of atherosclerosis^[@CR15]^. Few studies have investigated the atheroprotective effect of rituximab using clinical data. Hsue *et al*.^[@CR21]^ reported that rituximab improved endothelial function and reduced inflammation in patients with rheumatoid arthritis; however, they did not show a difference in ASCVD based on rituximab treatment.

There has been concern about cardiac complications after the use of rituximab to treat hematologic or rheumatologic diseases^[@CR22]--[@CR24]^. However, acute or delayed cardiac toxicity was suggested to be a result of cytokine release related to the infusion-related reaction rather than an aggravation of atherosclerosis. In addition, several randomized controlled trials showed that there was no difference in cardiac adverse events between patients with or without rituximab treatment for lymphoma and rheumatoid arthritis^[@CR25],[@CR26]^.

In the field of renal transplantation, there was only one report on rituximab and CVD. Tyden *et al*.^[@CR27]^ reported higher mortality from MI in patients treated with rituximab than in controls. That result came from a 3-year follow-up of a randomized control trial, but the number of participants was small, and there was no information about CVD risk factors. Also, the incidence of fatal MI was higher (about 10% during just 3 years of follow-up) compared with previous reports^[@CR4],[@CR5],[@CR28]^. The high rate of cardiac mortality might be attributable to other CVD-related patient factors rather than to an adverse effect of rituximab. In fact, another recently conducted randomized controlled trial has established a safety profile for rituximab in terms of serious adverse events in KT^[@CR29]^.

Rituximab is a monoclonal antibody that globally destroys CD 20-positive B cells. However, the aforementioned experimental evidence demonstrated that rituximab reduced atherosclerosis. That atheroprotective effect might come from the fact that atherogenic B2 cells are a major population of the adult human B cell repertoire^[@CR30]^. Another hypothesis is that because the peritoneal cavity provides rituximab resistance, resident B1 cells may be spared^[@CR31]^. Although the mechanism of the atheroprotective effect of rituximab is not yet known in humans, our results provide an important hint for investigating the role of B cell subsets in atherogenesis.

We found that the incidence of ASCVD was relatively low in our study population. Previous large-volume studies in Western populations have cited CVD rates of \~15% during 4--5 years of follow-up after KT^[@CR8],[@CR32]^, whereas that rate was only 6% during entire follow-up in our study. The difference might be due to dietary and lifestyle differences as well as the lower incidence of pretransplant ASCVD observed in Korea, compared to Western countries. Furthermore, more than 20% of patients were using statin before KT, so the mean LDL level (84.4 mg/dL) in our study exceeded by the mean (100 mg/dL) determined in Western studies. The relatively low incidence of CVD in Korean KT patients was also observed in another Korean study^[@CR33]^ and in a previous international cohort^[@CR4]^.

Anti-B-cell agents, including rituximab and B cell activating factor receptor antibody (belimumab), have been suggested as possible anti-atherogenic treatments^[@CR17]^, but there has not yet been a clinical study. In a situation where the number of KTs with prior desensitization is increasing^[@CR34]^, especially in Korea where LDKT prevails^[@CR35],[@CR36]^, our results provide clinical evidence to help understand the role of rituximab in ASCVD development.

Through subgroup analysis, we extended our investigation to various CVD risk factors and their influence on rituximab atheroprotection. Rituximab proved significantly protective in specific clinical subsets, namely DM, pretransplant dialysis, and older age ( ≥ 50 years); but no HRs proved significant in the absence of these factors. In addition, gender of KT recipients had no apparent impact on ASCVD in rituximab-treated patients. Adjusted HRs were unobtainable for subgroups, given the low event totals. However, assessment of matched subgroups revealed greater rituximab atheroprotection in patients at higher risk of ASCVD. A broad multicenter study, perhaps utilizing a national registry, would likely yield more conclusive results.

Despite our propensity-matched analysis, retrospective feature is still limitation of our study for which the results should be cautiously interpreted. Also, single center design is another major limitation. Prospective and multicenter study should be needed.

In conclusion, this study has demonstrated that rituximab induction reduces the rate of ASCVD during posttransplant periods. Furthermore, the atheroprotective effect of rituximab appears more advantageous for some KT recipients with heightened risks of ASCVD.

Methods {#Sec10}
=======

Patient selection {#Sec11}
-----------------

We conducted a retrospective study, accessing a database of 1,462 patients who underwent KT at Severance Hospital, Seoul, Korea, between January 2006 and December 2015. Exclusion criteria were as follows: (1) age \< 18 years at time of KT, (2) multiorgan transplantation, (3) rituximab use in treating antibody-mediated rejection after KT, and (4) acute coronary disease or patient death within 1 month after KT (2 fatal MIs, 2 nonfatal MIs, 2 death from cerebrovascular accidents, 1 non-cardiovascular death, 1 peripheral artery revascularization). Ultimately, 1299 patients qualified for analysis (Fig. [4](#Fig4){ref-type="fig"}).Figure 4Study population. KT, kidney transplantation; ASCVD, atherosclerotic cardiovascular disease.

Data collection {#Sec12}
---------------

We collected data on baseline characteristics of recipients and donors, lipid profiles, pretransplant use of statins, and BPAR within 1 year posttransplantation. SBP, DBP and eGFR were checked every 3 months. LDL concentrations were checked every 6 months for 1 year posttransplantation and annually thereafter. During posttransplant periods, we checked electrocardiography at least yearly. Patients with cardiac symptoms or electrocardiographic abnormalities were referred to a cardiologist for further evaluation. Those undergoing coronary revascularization were routinely followed by coronary angiography every 1--2 years, screening for restenosis or newly developed lesions. If suspected, patients were evaluated for acute cerebral infarction and peripheral arterial occlusive disease. We defined ASCVD as any of the following: fatal or nonfatal MI, coronary revascularization (by percutaneous intervention or surgery), acute cerebral infarction, or revascularization of peripheral arterial occlusion (by percutaneous intervention or surgery).

Rituximab use in desensitization protocol {#Sec13}
-----------------------------------------

Indications for rituximab induction were ABO-incompatible or crossmatch-positive KT (living donors, both instances) and ≥ 50% panel reactive antibodies prior to KT (living or deceased donors). In the event of LDKT, rituximab was given within 7--14 days in advance, delivering a single dose of 375 mg/m^2^. As of August 2013, rituximab dosing for ABO-incompatible LDKT was reduced to 200 mg if baseline anti-donor isoagglutinin IgG titers were ≤1:128^[@CR37]^. For deceased donor kidney transplantation, 200 mg of rituximab was given prior to operations as indicated. Standard regimens used at our institution for preoperative desensitization and postoperative immunosuppression are well described elsewhere^[@CR37]--[@CR39]^.

Study outcomes {#Sec14}
--------------

We compared composite ASCVD and all-cause mortality by rituximab induction in the matched cohort. Because the longest follow-up period in rituximab-treated patients was 102 months, we limited such comparisons to 8 years after KT. We also conducted subgroup analyses, examining various patient characteristics (DM, sex, required pretransplant dialysis, and age ≥ 50 years) to assess the potential influence of each in relation to ASCVD and rituximab use.

Statistical analysis {#Sec15}
--------------------

Propensity matching was undertaken to coordinate baseline characteristics of the two groups (with or without rituximab induction). Subsequent scores generated via logistic regression analysis included the following covariates, which differed for above groups or were known risk factors for CVD in KT recipients^[@CR4],[@CR28]^: age, sex, deceased donor, duration of dialysis, retransplantation, tacrolimus use, smoking, pretransplant DM, pretransplant ASCVD history, baseline LDL, and eGFR at 1 month. BPAR was not matched, because rituximab-treated patients had high risk for rejection by nature, and because BPAR had no impact on development of ASCVD in our entire cohort. Using the nearest neighbor method, we matched patients given rituximab to controls at 1:2 without replacement, setting the caliper at 0.25 width. All assessments were achieved using R freeware v3.5.0 (R Foundation for Statistical Computing, Vienna, Austria) with *MatchIt* package^[@CR40]^.

In comparing baseline characteristics of both groups before and after matching, data were expressed as mean ± standard deviation or median (interquartile range) for continuous variables and numbers (%) for categorical variables. Student's *t*-test, Mann-Whitney U test, or chi square test was applied as needed for group comparisons. We used Kaplan-Meier analysis to estimate differences in probabilities of ASCVD and all-cause mortality according to rituximab induction and calculated *P*-values by log-rank test. For estimates of ASCVD, death from causes other than ASCVD served for censoring.

In the matched cohort, we invoked Cox proportional-hazards regression analysis to assess the relation between rituximab induction and posttransplant ASCVD. Multivariable Cox regression entailed backward stepwise selection, based on covariates with *P*-values \< 0.05 in univariable analysis. Patients were further stratified by known CVD risk factors such as DM, sex, pretransplant dialysis, and age ≥ 50. To retain the homogeneity of rituximab and control groups, only matched pairs with or without specified variables qualified for subgroup analysis. Small ASCVD events in each subgroup prohibited multivariable Cox regression, so we presented only unadjusted HR of rituximab induction in subgroup analysis. All comparative and survival analyses relied on standard software (SPSS v23.0; IBM, Armonk, NY, USA), setting statistical significance at *P* \< 0.05.
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